Bevacizumab Intravitreal Injections Recalled for Lack of Sterility Assurance
RC Outsourcing is recalling Bevacizumab intravitreal injections due to lack of assurance of sterility. The recall affects 2,669 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a risk-of-harm product (injectable pharmaceutical for ophthalmic use) where injury has not yet been reported. The FDA Class II classification with lack of sterility assurance for an intravitreal injectable constitutes a potential serious hazard.
Plain-English summary
RC Outsourcing, LLC is recalling Bevacizumab 1.75 mg/0.07 mL intravitreal injections packaged in 0.25 mL syringes. The recall affects 2,669 syringes that were distributed nationwide in the United States.
The recall is issued due to lack of assurance of sterility. Bevacizumab is a prescription-only medication intended for hospital or office use only and must be refrigerated. The affected lot numbers are 20250708-768A26 (BUD October 6, 2025), 20250715-944DF2 (BUD October 13, 2025), 20250722-55C603 (BUD October 20, 2025), and 20250722-5DC113 (BUD October 20, 2025).
Healthcare facilities that have received or distributed this product should identify and stop using units from the affected lots immediately. Patients who may have received an injection from a recalled lot should contact their healthcare provider.
The recalled product
- Product
- Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
- Manufacturer
- RC Outsourcing, LLC
- Category
- Drug — Injectable / Ophthalmic
- Hazard
- sterility-assurance
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # 20250708-768A26
- BUD: Oct 06
- 2025 20250715-944DF2 BUD: Oct 13
- 2025 20250722-55C603 BUD: Oct 20
- 2025 20250722-5DC113 BUD: Oct 20
- 2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27